The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor

Daisuke Okui1 · Tomomitsu Sasaki1 · Masahiko Fushimi1 · Tetsuo Ohashi1

Received: 30 September 2019 / Accepted: 1 November 2019 / Published online: 16 November 2019
© The Author(s) 2019

Abstract
Background  Dotinurad, a novel selective urate reabsorption inhibitor (SURI), increases urinary uric acid excretion. The aim of this study is to examine the pharmacokinetics, pharmacodynamics, and safety of dotinurad according to the type of hyperuricemia, with or without concomitant use of xanthine oxidase inhibitor, in uric acid “overproduction type” patients.

Methods  This open-label clinical pharmacology study was conducted in a hospital. Dotinurad 1 mg was administered for 7 days to hyperuricemic patients with uric acid “overproduction type” (overproduction group, n = 6; and combination group, n = 6) and uric acid “underexcretion type” (underexcretion group, n = 6). In the combination group, topiroxostat 80 mg was used concomitantly.

Results  No significant differences were observed in pharmacokinetics and safety between overproduction group and underexcretion group, and the percent change in serum uric acid level and the amount of urinary uric acid excretion after administration were comparable. In “overproduction type” patients of combination group, the percent change in serum uric acid level significantly increased and the amount of urinary uric acid excretion significantly decreased compared to those of overproduction group. No clinically meaningful differences were observed in safety between the overproduction group and the combination group.

Conclusion  In inpatients, differences in hyperuricemic type did not significantly influence the pharmacokinetics, pharmacodynamics, and safety of dotinurad. Moreover, in “overproduction type”, the coadministration of dotinurad and topiroxostat had an add-on serum uric acid lowering effect and suppressed urinary uric acid excretion.

Trial registration ClinicalTrials.gov Identifier: NCT02837198.

Keywords  Hyperuricemia · Selective urate reabsorption inhibitor · URAT1 inhibitor · Dotinurad · Uric acid overproduction type · Topiroxostat

Introduction

Persistent hyperuricemia can lead to urate crystal deposition diseases such as gouty arthritis, urinary tract calculi and renal impairment [1]. Properly maintaining serum uric acid levels is important for the prevention of these diseases and can further lead to the protection of renal function and the reduction of cardiovascular disease risk [2, 3].

Improving lifestyle is important in the treatment of hyperuricemia. It is however difficult to relieve the symptoms of patients with repeated gouty arthritis or with gouty tophus by merely improving lifestyle: hyperuricemic
treatment should thus be conducted to maintain serum uric acid levels ≤ 6.0 mg/dL [1]. Hyperuricemia is mainly classified into three types according to cause: uric acid overproduction “overproduction type”; decrease in uric acid excretion “underexcretion type”; and the combination of both “combined type”. In Japan, prevalence of each is estimated to be 10%, 60%, and 30%, respectively [1]. Japanese guidelines for the management of hyperuricemia and gout recommend treating “underexcretion type” with uricosuric drugs (benzbromarone, probenecid) and “overproduction type” with xanthine oxidase inhibitors (XOIs) (allopurinol, febuxostat). For “overproduction type”, the administration of uricosuric drugs is considered inappropriate because that increases the risk of urinary calculi [4].

Dotinurad is a novel selective urate reabsorption inhibitor (SURI), that selectively inhibits urate transporter 1 (URAT 1). In non-clinical study, it was confirmed that the inhibition of uric acid reabsorption by administrating dotinurad results in the promotion of uric acid excretion into urine and the reduction of serum uric acid levels [5]. Since dotinurad promotes the excretion of uric acid into the urine, according to the Japanese management guidelines it would be primarily administered to “underexcretion type” patients. However, in the clinical setting, improvement in serum uric acid levels or relief of symptoms such as gouty attacks during pharmacotherapy may affect the patient’s lifestyle, such as eating habits, and lead to a change in the hyperuricemic type [6]. This is probably because changes in body purine intake from diet, as well as changes in the total body pool resulting from treatment, affect changes in urinary urate excretion, one of the indicators used for hyperuricemia classification. In addition, the possibility of dotinurad being administered to “overproduction type” patients cannot be ruled out, given that the fundamental principle of the Japanese management guidelines may sometimes not be observed in selecting drugs to avoid side effects [4]. Therefore, we considered it useful and necessary to examine the pharmacokinetics (PK), pharmacodynamics (PD), and safety of dotinurad in “overproduction type” patients.

Japanese management guidelines also report that concomitant therapy with XOIs and uricosuric drugs is effective [7, 8], and these drugs can be used concomitantly in clinical settings. Dotinurad and an XOI may thus be used together clinically. Therefore, we considered the PK, PD, and safety investigations of the concomitant use of dotinurad and an XOI (topiroxostat) should be required.

Methods

Study design

This Japanese study was conducted as an open-label, 7-day, multiple dose clinical pharmacology study in hospitalized Japanese patients. Classification of hyperuricemia was conducted twice, once at screening and once on the day before initial administration (day − 1).

Patients who were deemed eligible for participation in this study at the screening examination were hospitalized and underwent hyperuricemia classification on day − 1. “Underexcretion type” patients were assigned to the underexcretion group. On the other hand, “overproduction type” patients were assigned to either the overproduction group or combination group. The patients in the overproduction and underexcretion groups were treated with dotinurad 1 mg; those in the combination group were treated with dotinurad 1 mg and topiroxostat 80 mg (Fig. 1). Patients received study drugs for 7 days (days 1–7) once daily after breakfast. The health status of the patients who completed study drug administration was assessed for 2 days (days 8–9) after the final administration. During days 1–9, colchicine and citrate were concomitantly administered to prevent gouty attacks and urinary calculi.
Protocol amendment

In the initial protocol of this study, the patients were hospitalized for 4 days before initial administration and had low purine intake based on the Japanese management guidelines. However, during the hospitalization period until the initial administration, the meals and living environment were very different from the usual lifestyle pattern of these patients. Therefore, the hyperuricemic type on day −1 changed from that reported at screening, and none of “overproduction type” patients could participate in this study. We thus modified the protocol (i.e., the hospitalization period before initial administration was reduced to 1 day). Although six “underexcretion type” patients had already completed administration using the initial protocol, we decided that the study should be conducted again in all groups using the modified protocol because all groups required evaluation under the same conditions, based on the study aims. “Underexcretion type” patients who had completed administration before the protocol amendment were not used in the analyses of this study because the protocol differed from that of the other patients, and their results are shown as the ‘reference group’ in a supplement.

Inclusion and exclusion criteria

The main inclusion criteria of this study are described below. Patients with serum uric acid levels ≥7.0 mg/dL at screening examination and on day −1; patients who were classified as “overproduction type” or “underexcretion type”; and male patients aged at least 20 years.

The main exclusion criteria are described below.

Patients with a history of surgery involving the digestive organs (e.g., the gastrointestinal tract, liver, gallbladder, bile duct, pancreas) or kidney, excluding surgery not affecting drug absorption (e.g. cecum and hemorrhoid surgery); patients who changed the dosage of drugs or used drugs that may affect serum uric acid levels in the 14 days between the screening examination and initial administration; patients with a history of allergy (including hypersensitivity) to topiroxostat, the combination of potassium citrate and sodium citrate hydrate, or colchicine; patients with a history of urinary calculus or patients with a urinary calculus observed on abdominal ultrasonography or simple abdominal X-ray examinations at the screening examination; patients with an eGFR <30 mL/min/1.73 m² at the screening examination; patients who consumed alcohol after the day prior to admission; patients who consumed grapefruit or substances containing grapefruit within 7 days before the day of admission; patients who consumed Hypericum perforatum (St. John wort) or substances containing Hypericum perforatum within the 4 weeks before admission; patients who had previously participated in clinical trials of dotinurad and received administration of the study drug; patients otherwise judged to be unsuitable for participation in this study by the principal investigator.

Blood and urine sample collection

Plasma samples were collected 25 times for PK measurements. Blood samples were obtained at the following times: on days 1 and 7, before administration and 0.5, 1, 2, 3, 4, 6, 8, and 12 h after administration; on days 2–6, before administration; on days 8 and 9, 24 and 48 h after the final administration. Serum samples were collected 28 times for PD measurements. Blood samples were obtained at the following times: on days 1, 4, and 7, before administration and 1, 2, 4, 8, and 12 h after administration; on days 2, 3, 5, and 6, before administration and 12 h after administration; on days 8 and 9, 24 and 48 h after the final administration. Urine samples were collected at the following times: on day −1, between 24 h before initial administration and just before initial administration; on days 1–7, between 0 and 24 h after administration each day; on day 8, between 24 and 48 h after the final administration.

Classification of hyperuricemia

Hyperuricemia was classified into the following four types based on uric acid measurement in the 60-min urine collection at screening and on day −1 [4]: (1) uric acid overproduction type, urinary excretion of uric acid (EUA) >0.51 mg/kg/h and uric acid clearance (CUA) ≥7.3 mL/min/1.73 m²; (2) uric acid underexcretion type, EUA <0.48 or CUA <7.3; (3) combined type, EUA >0.51 and CUA <7.3; and (4) normal type, 0.48 ≤EUA ≤0.51 and CUA ≥7.3. Patients classified as combined type and normal type were excluded from this study.

Analytical methods

The dotinurad concentration in the plasma was measured using liquid chromatography-tandem mass spectrometry (LC–MS/MS) at the research institute, Fuji Yakuhin Co., Ltd. The Agilent 1100 series HPLC system (Agilent Technologies, USA) was used for the liquid chromatography; API3000 (AB SCIEX, USA) was used for the mass spectrometry; and Inertsil ODS-3 (150 mm ×2.1 mm, 3 μm, GL Sciences Inc., Japan) was used for the analysis column. Dotinurad concentrations were measured using 5 mmol/L ammonium acetate solution (pH 4.0)/methanol (50:50) in the mobile phase.
The lower limit of quantification was 1 ng/mL for measurement of dotinurad concentration in plasma.

Uric acid concentrations in serum and urine were measured by the enzyme method at the clinical trial institution.

**Pharmacokinetic analyses**

The PK parameters of dotinurad were calculated by the non-compartmental model using WinNonlin V6.4. The main PK parameters used for the PK evaluation were as follows: maximum plasma concentration (C<sub>max</sub>), time to reach the peak plasma concentration (T<sub>max</sub>), elimination half-life (T<sub>1/2</sub>), area under the plasma concentration–time curve from time zero to infinity (AUC<sub>0-inf</sub>), elimination rate constant (kel), distribution volume/fraction of dose absorbed (Vd/F), total clearance/fraction of dose absorbed (CL<sub>tot/F</sub>), and mean residence time from zero to infinity (MRT<sub>0-inf</sub>). The AUC was calculated using the linear trapezoidal method by selecting linear trapezoidal linear interpolation as the WinNonlin calculation method.

**Pharmacodynamic analyses**

The PD parameters were as follows: delta maximum effective concentration (ΔEC<sub>max</sub>), delta area under the serum concentration–time curve (ΔAUEC<sub>0-24</sub>), maximum reduction rate, amount of uric acid excreted in urine from time zero to 24 h (AE<sub>0-24</sub>), renal clearance from time zero to 24 h (CL<sub>R0-24</sub>), and fractional uric acid excretion from time zero to 24 h (FE<sub>0-24</sub>). ΔAUEC<sub>0-24</sub> was calculated from AUEC<sub>24-0</sub> and AUEC<sub>0-24</sub>. AUEC<sub>24-0</sub> was calculated by extrapolating the serum uric acid level before initial administration on the day of initial administration to 24 h before initial administration. FE<sub>0-24</sub> was calculated by correcting CL<sub>R0-24</sub> using creatinine clearance.

**Safety evaluations**

Adverse events (AEs), adverse drug reactions (ADRs), and safety assessments were conducted by principle investigators based on clinical laboratory test values (including Ccr), vital signs, and 12-lead electrocardiography. AEs were classified according to the system organ class and preferred term (MedDRA/J ver. 20.0; Japanese Maintenance Organization, Tokyo, Japan) and were evaluated in terms of their potential causality with the study drug, severity, and seriousness. AEs for which a causal relationship with the study drug could not be ruled out by the investigator were considered to be ADRs.

**Statistical analyses**

The number of subjects per group was determined to be six as minimum required one to evaluate pharmacokinetics and pharmacodynamics.

Statistical analyses were performed using SAS system version 9.2 (SAS Institute, Cary, NC, USA). For comparisons between groups, the Dunnett multiple comparison test was used with a two-sided significance level of 5%. Dunnett multiple comparison was performed for the underexcretion group and the combination group by setting the overproduction group as the standard. Paired t-tests were performed to compare measurements before and after administration.

Differences in hyperuricemic types were compared in the overproduction group and underexcretion group. Conversely, a comparison between “overproduction type” patients with/without coadministration of topiroxostat was conducted in the overproduction group and the combination group, where dotinurad monotherapy was administered in the overproduction group and concomitant therapy with dotinurad and topiroxostat was administered in the combination group.

**Results**

**Subjects**

Informed consent for this study was obtained from 381 patients. After screening, 284 patients were excluded and 97 patients were hospitalized. Of the 97 patients, 73 were excluded. The main reason for exclusion was the hyperuricemic type at screening or day − 1. Finally, study drugs were administered to 24 hyperuricemic patients (six patients in each group). Of the 24 treated patients, one patient (reference group) discontinued the study (Fig. 2). The discontinued patient met the prespecified discontinuation criteria (the urinary uric acid excretion increased by ≥15% from day 1 of administration). No differences in characteristics of patients were observed among all groups (Table 1).

**Pharmacokinetics**

**PK of dotinurad in the overproduction and underexcretion groups**

In the overproduction and underexcretion groups, the mean plasma dotinurad concentrations at all timepoints on day 1 were comparable (Fig. 3). In these groups, all PK parameters (C<sub>max</sub>, T<sub>max</sub>, T<sub>1/2</sub>, AUC<sub>0-inf</sub>, CL<sub>tot/F</sub>, kel, Vd/F, and MRT<sub>0-inf</sub>) were comparable (Table 2).
PK of dotinurad in the combination group

In the combination group, the mean plasma dotinurad concentrations were not affected by topiroxostat at all timepoint on day 1 compared with those of the overproduction group (Fig. 3). All PK parameters of dotinurad with/without coadministration of topiroxostat were also comparable (Table 2).

Pharmacodynamics

Serum uric acid in the overproduction and underexcretion groups

The percent change in serum uric acid level after the initial administration of dotinurad increased in a similar manner in both the overproduction group and the underexcretion group (Fig. 4). Additionally, the ΔEC\textsubscript{max} and maximum reduction

---

Table 1 Summary of the baseline characteristics

| Category                      | Treatment groups                                      | Overproduction (n = 6) | Underexcretion (n = 6) | Combination (n = 6) |
|-------------------------------|-------------------------------------------------------|-----------------------|------------------------|---------------------|
| Age (year)                    |                                                       | 63.0 ± 9.7            | 52.8 ± 8.2             | 50.3 ± 6.0          |
| Height (cm)                   |                                                       | 170.85 ± 4.73         | 164.35 ± 2.54          | 169.32 ± 3.68       |
| Weight (kg)                   |                                                       | 72.62 ± 9.85          | 69.40 ± 6.54           | 77.67 ± 7.62        |
| BMI (kg/m\(^2\))              |                                                       | 24.92 ± 3.68          | 25.75 ± 2.98           | 27.05 ± 2.01        |
| eGFR (mL/min/1.73 m\(^3\))    |                                                       | 74.0 ± 14.1           | 73.7 ± 8.4             | 80.8 ± 4.4          |
| Serum uric acid level (mg/dL) |                                                       | 7.68 ± 0.47           | 8.30 ± 0.93            | 8.32 ± 0.50         |

Values are presented as the mean ± SD

eGFR (mL/min/1.73 m\(^3\)) = 194 × Serum creatinine\(^{-1.094}\) × Age\(^{-0.287}\)

BMI body mass index

---
Fig. 3 Change in plasma concentration of dotinurad on day 1 in the overproduction, underexcretion, and combination groups. Error bars indicate standard deviation.

Table 2 PK parameters of dotinurad in plasma and urine on days 1 and 7 in the overproduction, underexcretion, and combination groups.

| Parameters | Treatment groups | Overproduction (n = 6) | Underexcretion (n = 6) | Combination (n = 6) |
|------------|------------------|-----------------------|------------------------|-------------------|
| $C_{\text{max}}$ (ng/mL) | Day 1 | 78.68 ± 14.92 | 83.80 ± 9.77 | 83.28 ± 10.22 |
| | Day 7 | 102.90 ± 21.43 | 101.20 ± 18.28 | 108.33 ± 15.49 |
| $T_{\text{max}}$ (h) | Day 1 | 3.50 ± 0.55 | 4.00 ± 0.00 | 3.17 ± 0.41 |
| | Day 7 | 3.67 ± 0.52 | 3.17 ± 0.98 | 3.67 ± 0.52 |
| $T_{1/2}$ (h) | Day 1 | 11.67 ± 1.92 | 10.24 ± 1.32 | 11.37 ± 2.23 |
| | Day 7 | 11.49 ± 1.49 | 10.44 ± 0.66 | 10.83 ± 0.96 |
| AUC$_{0-\text{inf}}$ (ng h/mL) | Day 1 | 1277.29 ± 490.68 | 1224.51 ± 197.78 | 1274.93 ± 155.18 |
| | Day 7 | 1688.49 ± 633.70 | 1561.90 ± 257.42 | 1688.15 ± 354.21 |
| $C_{\text{max}}/F$ (L/h) | Day 1 | 0.86 ± 0.24 | 0.83 ± 0.14 | 0.79 ± 0.61 |
| | Day 7 | 0.64 ± 0.12 | 0.66 ± 0.17 | 0.61 ± 0.13 |
| kel (1/h) | Day 1 | 0.0608 ± 0.0101 | 0.0686 ± 0.0089 | 0.0627 ± 0.0104 |
| | Day 7 | 0.0611 ± 0.0071 | 0.0666 ± 0.0043 | 0.0644 ± 0.0051 |
| Vd/F (L) | Day 1 | 13.93 ± 2.59 | 12.14 ± 0.82 | 12.84 ± 1.64 |
| | Day 7 | 10.39 ± 1.94 | 9.81 ± 1.27 | 9.52 ± 1.75 |
| MRT$_{\text{inf}}$ (h) | Day 1 | 17.68 ± 3.02 | 15.74 ± 2.00 | 16.77 ± 3.38 |
| | Day 7 | 16.78 ± 2.23 | 14.88 ± 1.09 | 15.53 ± 1.63 |

Data are presented as mean ± SD.
rates were comparable in both groups (Table 3). Regarding the ΔAUEC_{0-24} on days 1, 4, and 7, no significant differences were observed at all timepoints in both groups.

**Urinary uric acid in the overproduction and underexcretion groups**

In the overproduction and underexcretion groups, Ae_{0-24} fluctuated in a similar manner (Fig. 5, Table 4). AE_{0-24} on day −1 of both groups were 673.40 and 516.25 mg, and on day 1 increased to 1289.33 and 1132.30 mg, respectively. In contrast, on day 2, those decreased to 951.45 and 882.17 mg, respectively. From day 4, these fluctuations were comparable degree in both groups.

Comparison of uric acid clearance (CL_{R0-24}) on days 1, 4, and 7 in both groups, no significant differences were observed at all timepoints. Furthermore, regarding FE_{0-24} on days 4 and 7, no significant differences were observed at all timepoints.

**Serum uric acid in the combination group**

In the combination group, the percent change in serum uric acid level increased at all timepoints compared to those of the overproduction group (Fig. 4). Furthermore, the ΔEC_{max} and maximum reduction rate were higher than those of the overproduction group. When comparing the ΔAUEC_{0-24} of the combination group to those of the overproduction group, significant differences were observed at all timepoints (Table 3).
Fig. 5 Change in the urinary uric acid excretion in the overproduction, underexcretion, and combination groups. Error bars indicates standard deviation. $Ae$ amount of urate excreted in urine

Table 4 PD parameters of urine uric acid levels in the overproduction, underexcretion, and combination groups

| Parameters | Treatment groups | $P$ value* |  |
|------------|------------------|------------|
|            | Overproduction ($n = 6$) | Underexcretion ($n = 6$) | Combination ($n = 6$) |
| $Ae_{0-24}$ (mg) |  |  |  |
| Day − 1 | 673.40 ± 85.52 | 516.25 ± 76.62 | 858.92 ± 108.63 | – |
| Day 1 | 1289.33 ± 126.45 | 1132.30 ± 104.21 | 1187.77 ± 104.29 | – |
| Day 2 | 951.45 ± 95.98 | 882.17 ± 132.88 | 829.33 ± 66.85 | – |
| Day 3 | 890.43 ± 82.41 | 804.60 ± 101.73 | 695.25 ± 75.70 | – |
| Day 4 | 838.15 ± 48.69 | 816.02 ± 98.22 | 616.40 ± 62.45 | – |
| Day 5 | 792.85 ± 91.37 | 758.12 ± 84.21 | 612.55 ± 64.36 | – |
| Day 6 | 810.43 ± 77.87 | 765.65 ± 110.89 | 619.17 ± 72.05 | – |
| Day 7 | 790.30 ± 58.99 | 760.50 ± 82.88 | 621.88 ± 92.18 | – |
| Day 8 | 483.35 ± 48.80 | 439.25 ± 101.73 | 438.77 ± 36.35 | – |
| $CL_{0-24}$ (mL/min) |  |  |  |
| Day − 1 | 5.77 ± 0.64 | 4.14 ± 0.68 | 6.96 ± 1.33 | 0.017*/0.079 |
| Day 1 | 15.34 ± 2.21 | 12.50 ± 3.18 | 15.25 ± 4.93 | 0.361/0.999 |
| Day 4 | 14.92 ± 2.03 | 13.33 ± 1.75 | 13.86 ± 3.80 | 0.511/0.232 |
| Day 7 | 14.13 ± 2.23 | 12.60 ± 1.36 | 13.60 ± 3.53 | 0.490/0.909 |
| $FE_{0-24}$ (%) |  |  |  |
| Day − 1 | 4.77 ± 0.89 | 3.57 ± 0.64 | 4.93 ± 1.08 | 0.060/0.939 |
| Day 4 | 12.29 ± 2.04 | 11.04 ± 2.26 | 10.35 ± 2.10 | 0.511/0.232 |
| Day 7 | 11.76 ± 1.68 | 10.26 ± 1.51 | 10.25 ± 2.33 | 0.308/0.305 |

Data are presented as the mean ± SD
*P < 0.05 (vs overproduction group)

*Dunnett multiple comparison test was applied to the underexcretion group and the combination group, setting the overproduction group as the control group.
Urinary uric acid in the combination group

The fluctuation of $Ae_{0-24}$ in the combination group was similar to those in the overproduction group (Fig. 5, Table 4). At all timepoints, $Ae_{0-24}$ in the combination group were lower than those in the overproduction group.

Regarding uric acid clearance ($CLR_{0-24}$) and $FE_{0-24}$, no significant differences were observed between the overproduction group and the combination group, at all timepoints.

Safety

The AE incidence rates were 33.3% (two patients, eight events) in the underexcretion group, 16.7% (one patient, one events) in the combination group, and none in the overproduction group (Table 5). An ADR was observed in one patient (alanine aminotransferase increased) in the combination group. The severity of the ADR was mild, and the patient recovered without treatment. No serious adverse event was observed in any group.

Discussion

Difference of hyperuricemic types

This study showed no differences in the PK of dotinurad between the overproduction and underexcretion groups.

Regarding PD, serum uric acid lowering effects were comparable and the time-course of $Ae_{0-24}$ was similar in both groups. Moreover, when dotinurad was administered continuously, the $Ae_{0-24}$ in both groups indicated comparable levels. There were no clinically meaningful differences in safety between patients with these hyperuricemic types.

We considered that it was necessary to investigate what degree urinary uric acid excretion changes when dotinurad is administered repeatedly in “overproduction type” patients, as the drug promotes uric acid excretion into urine. From our study results, “overproduction type” patients in whom urinary uric acid excretion increases continuously were not observed, and the urinary uric acid

Table 5

| Summary of adverse events | Adverse events | Treatment groups |
|---------------------------|---------------|-----------------|
|                           |               | Overproduction  |
|                           |               | Underexcretion  |
|                           |               | Combination    |
|                           |               | $(n=6)$ (%)     | $(n=6)$ (%)     | $(n=6)$ (%)     |
| All                       | 0 (0.0%)      | 2 (33.3)        | 1 (16.7)        |
| Nervous system disorders  | 0 (0%)        | 1 (16.7%)       | 0 (0%)          |
| Headache                  | 0 (0%)        | 1 (16.7)        | 0 (0)           |
| Eye disorders             | 0 (0%)        | 1 (16.7%)       | 0 (0%)          |
| Eye pain                  | 0 (0%)        | 1 (16.7)        | 0 (0)           |
| Respiratory, thoracic and mediastinal disorders | 0 (0%) | 2 (33.3%) | 0 (0%) |
| Oropharyngeal swelling    | 0 (0%)        | 1 (16.7)        | 0 (0)           |
| Oropharyngeal pain        | 0 (0%)        | 1 (16.7)        | 0 (0)           |
| Gastrointestinal disorders| 0 (0%)        | 1 (16.7%)       | 0 (0%)          |
| Abdominal distension      | 0 (0%)        | 1 (16.7)        | 0 (0)           |
| Abdominal pain            | 0 (0%)        | 1 (16.7)        | 0 (0)           |
| Musculoskeletal and connective tissue disorders | 0 (0%) | 1 (16.7%) | 0 (0%) |
| Neck pain                 | 0 (0%)        | 1 (16.7)        | 0 (0)           |
| Investigations            | 0 (0%)        | 0 (0%)          | 1 (16.7%)       |
| Alanine aminotransferase increased | 0 (0%) | 0 (0) | 1 (16.7) |

Incidence (%) = number of patients/number of analyzed patients × 100

Table 6

| Change in hyperuricemic type in inpatients with overproduction |
|--------------------------------------------------------------|
| Hyperuricemic type (Screening vs day -1)                      |
| Hyperuricemic type                                           | Total |
| Changed           | Unchanged |           |
| With hospitalization (original protocol)†                   | 16     | 0         | 16    |
| Without hospitalization (amendment)‡                         | 15     | 10        | 25    |
| Total             |           |           | 31     | 10    | 41    |

†Patients who were hospitalized during the run-in period and had restricted daily living including eating and drinking
‡Patients who were not hospitalized during the run-in period and maintained their normal activities of daily living
excretion temporarily increased but later decreased. This was similar to fluctuations of urinary uric acid excretion found in “underexcretion type” patients. Furthermore, continuous administration of dotinurad resulted in the comparable amount of urinary uric acid excretion in both type patients. Therefore, we conjectured that the risk of urinary calculus with dotinurad may not be substantially different between these two types.

**Coadministration of XOI (topiroxostat)**

In “overproduction type” patients, we found that concomitant administration of dotinurad and topiroxostat showed an add-on serum uric acid lowering effect and suppression of urinary uric acid excretion, compared to the administration of dotinurad monotherapy. We hypothesize that the concomitant use of topiroxostat reduced the amount of uric acid production in the body, thereby suppressing urinary uric acid excretion. No clinically meaningful differences in safety were observed between dotinurad monotherapy and concomitant therapy with topiroxostat.

In this study, with patient lifestyle controlled under hospitalization, all patients classified as the “overproduction type” at screening had changed to other hyperuricemic type by day − 1, even though dotinurad had not been administered. Most of these patients changed to “underexcretion type” (Table 6). Conversely, changes in hyperuricemic type were rarely observed in “underexcretion type” patients (Table 7). Therefore, most of the patients classified as “overproduction type” may have fallen into temporary overproduction condition of uric acid due to the effects of environmental factors (e.g., excessive intake of purines or calories, or alcohol consumption). We can therefore speculate that only a few “overproduction type” patients are classified as such due to intrinsic factors, and most are apparent “overproduction type” due to environmental factors associated with their individual lifestyle.

From the above, concomitant therapy with dotinurad and XOI appears to be a reasonable treatment. In Japan, although the primary cause for hyperuricemia is considered to be decreased uric acid excretion, the findings obtained in this study suggest that many “underexcretion type” patients exhibit temporary overproduction characteristics due to lifestyle-associated environmental factors. In this study, most of the patients classified as “overproduction type” changed to “underexcretion type” when lifestyle was controlled. In considering the disposition of uric acid in many Japanese people with hyperuricemia, suppressing uric acid production while simultaneously promoting uric acid excretion in urine may be a reasonable treatment method.

This was the first study to administer dotinurad to “overproduction type” patients; thus, it was conducted as a 7-day, multiple-dose study under conditions of hospitalization where meal and lifestyle environments were strictly controlled. In the future, however, long-term clinical studies must be conducted in outpatients to generalize the results obtained in this study.

**Acknowledgements** We are grateful to the investigators, local study coordinators, and patients for their valuable contributions to this study; Koichi Nakamura of Clinical Research Hospital Tokyo, for carefully proofreading the manuscript.

**Compliance with ethical standards**

**Conflict of interest** Fuji Yakuhin Co., Ltd. (Fuji) the manufacturer of dotinurad sponsored this study. All authors were employees of Fuji.

**Ethical standards** The study protocol and informed consent document were reviewed and approved by an institutional review board (SHINAGAWA EAST ONE Medical Clinic; Tokyo, Japan). Informed consent was obtained from all individual participants included in the study. The tests were conducted in compliance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Good Clinical Practice guidelines, and other applicable regulatory requirements. The information of this study was registered with ClinicalTrials.gov (ClinicalTrials.gov number: NCT02837198).

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Japanese Society of Gout and Nucleic Acid Metabolism: guideline for the management of hyperuricemia and gout: 3rd edition. Tokyo; 2018. p. 72–3, p. 95–8, p. 114–7.

2. Siu YP, Leung KT, Tong MKH, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.
3. Athyros VG, Elisaf M, Bouloukos VI, et al. Pathogenesis and treatment of kidney disease and hypertension. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek atorvastatin and coronary-heart-disease evaluation (GREACE study). Am J Kidney Dis. 2004;43:589–99.

4. Yamanaka H. Japanese Society of Gout and Nucleic Acid Metabolism: guideline for the management of hyperuricemia and gout: 2nd edition. Tokyo; 2010. p. 83–6.

5. Taniguchi T, Ashizawa N, Matsumoto K, et al. Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor. J Pharmacol Exp Ther. 2019;371:162–70.

6. Tsutani H, Kiriba C, Imamura S, et al. Latent overproductive hyperuricemia increases in patients during the intermittent phase of gouty arthritis long-term antihyperuricemic treatment. Mod Rheumatol. 2000;10:207–10.

7. Hosoya T, Ichida K, Tabe A, et al. Combined therapy using allopurinol and benz bromarone for gout and hyperuricemia complicated with renal disorder. Jpn J Rheumatol. 1992;4:77–90.

8. Ohno I, Okabe H, Yamaguchi Y, et al. Usefulness of combination treatment using allopurinol and benz bromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxy purinol. Jpn J Nephrol. 2008;50:506–12.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.